Fig. S1. The schematic illustration of the synthesis of opto-pomalidomide and the working model for opto-pomalidomide to achieve light-induced degradation of IKZF1/3. Fig. S2 . UPLC-MS characterization and the time-dependent uncaging of pomalidomide and opto-pomalidomide. Fig. S3 . Uncaging of opto-pomalidomide by UVA irradiation leads to active degradation of IKZFs in multiple myeloma cancer cell lines. Fig. S4 . The schematic illustration of the synthesis of opto-dBET1 and the working model for opto-dBET1 to achieve light-induced degradation of BRDs. Fig. S5 . UPLC-MS characterization and the time-dependent uncaging of opto-dBET1 by UVA irradiation in vitro. Fig. S6 . dBET1 inhibits cell proliferation in a CRBN-dependent manner. Fig. S7 . The schematic illustration of the synthesis of opto-dALK and the working model for opto-dALK to achieve light-induced degradation of ALK fusion proteins. Fig. S8 . UPLC-MS characterization and the time-dependent uncaging process of opto-dALK. Fig. S9 . Dose-dependent degradation of ALK fusion proteins by dALK.
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